Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022-Reference-Cited by-同舟云学术

Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022

Published:2023-02-16 Issue:7 Volume:28 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Huiberts Anne J¹,de Gier Brechje¹,Hoeve Christina E¹,de Melker Hester E¹,Hahné Susan JM¹,den Hartog Gerco²¹,van de Wijgert Janneke HHM³¹,van den Hof Susan¹,Knol Mirjam J¹

Affiliation:

1. Centre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands

2. Radboud Centre for Infectious Diseases, Radboudumc, Nijmegen, the Netherlands

3. Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht (UMCU), Utrecht, the Netherlands

Abstract

We used data of 32,542 prospective cohort study participants who previously received primary and one or two monovalent booster COVID-19 vaccinations. Between 26 September and 19 December 2022, relative effectiveness of bivalent original/Omicron BA.1 vaccination against self-reported Omicron SARS-CoV-2 infection was 31% in 18–59-year-olds and 14% in 60–85-year-olds. Protection of Omicron infection was higher than of bivalent vaccination without prior infection. Although bivalent booster vaccination increases protection against COVID-19 hospitalisations, we found limited added benefit in preventing SARS-CoV-2 infection.

Publisher

European Centre for Disease Control and Prevention (ECDC)

Subject

Virology,Public Health, Environmental and Occupational Health,Epidemiology

Reference13 articles.

1. World Health Organization (WHO). One year since the emergence of COVID-19 virus variant Omicron. Geneva: WHO; 2022. Available from: https://www.who.int/news-room/feature-stories/detail/one-year-since-the-emergence-of-omicron

2. European Medicines Agency (EMA). First adapted COVID-19 booster vaccines recommended for approval in the EU. EMA; 2022. Available from: https://www.ema.europa.eu/en/news/first-adapted-covid-19-booster-vaccines-recommended-approval-eu

3. Rijksinstituut voor Volksgezondheid en Milieu (RIVM). Varianten van het coronavirus SARS-CoV-2.[Variants of the coronavirus SARS-CoV-2]. Bilthoven: RIVM; 2023. Dutch. Available from: https://www.rivm.nl/coronavirus-covid-19/virus/varianten

4. Design and baseline description of an observational population-based cohort study on COVID-19 vaccine effectiveness in the Netherlands - The VAccine Study COvid-19 (VASCO);Huiberts;Research Square,2022

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and antibody responses of Omicron BA.4/5 bivalent booster vaccine among hybrid immunity with diverse vaccination histories: A cohort study;Vaccine: X;2024-10

2. Repeated COVID-19 mRNA vaccination results in IgG4 class switching and decreased NK cell activation by S1-specific antibodies in older adults;Immunity & Ageing;2024-09-14

3. Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study;The Lancet Microbe;2024-08

4. Initial Developments to Contain SARS-CoV-2 Spread and the Viability of the Virus on Different Surfaces and Environments;European Journal of Medical and Health Sciences;2024-07-20

5. A systematic review and meta-analysis on the effectiveness of bivalent mRNA booster vaccines against Omicron variants;Vaccine;2024-05